



CLAIMS

1. A compound having formula (I) or formula (II):



(I)



(II)

and pharmaceutically acceptable derivatives thereof,  
wherein:

- 10 X is O, S, C(R<sup>1</sup>)<sub>2</sub> or NR<sup>1</sup>;  
y is 1 or 2;

- A, B and R<sup>1</sup> are independently E, (C<sub>1</sub>-C<sub>10</sub>)-straight or  
branched alkyl, (C<sub>2</sub>-C<sub>10</sub>)-straight or branched alkenyl or  
alkynyl, or (C<sub>5</sub>-C<sub>7</sub>)-cycloalkyl or cycloalkenyl; wherein 1  
15 or 2 hydrogen atoms in said alkyl, alkenyl or alkynyl are  
optionally and independently replaced with E, (C<sub>5</sub>-C<sub>7</sub>)-  
cycloalkyl or cycloalkenyl; and wherein 1 to 2 methylene  
(-CH<sub>2</sub>-) groups in said alkyl, alkenyl, or alkynyl groups  
are optionally and independently replaced by -O-, -S-,  
20 -S(O)-, -S(O)<sub>2</sub>-, =N-, -N= or -N(R<sup>3</sup>)-;

or B and R<sup>1</sup> are independently hydrogen;

- wherein R<sup>3</sup> is selected from hydrogen, (C<sub>1</sub>-C<sub>4</sub>)-  
straight or branched alkyl, (C<sub>3</sub>-C<sub>4</sub>)-straight or branched  
alkenyl or alkynyl, or (C<sub>1</sub>-C<sub>4</sub>) bridging alkyl, wherein  
25 said bridge is formed between the nitrogen atom to which  
said R<sup>3</sup> is bound and any carbon atom of said alkyl,  
alkenyl or alkynyl to form a ring, and wherein said ring

is optionally benzofused;

wherein E is a saturated, partially saturated or unsaturated, or aromatic monocyclic or bicyclic ring system, wherein each ring comprises 5 to 7 ring atoms  
5 independently selected from C, N, O or S; and wherein no more than 4 ring atoms are selected from N, O or S;

wherein 1 to 4 hydrogen atoms in E are optionally and independently replaced with halogen, hydroxyl, hydroxymethyl, nitro, SO<sub>3</sub>H, trifluoromethyl,  
10 trifluoromethoxy, (C<sub>1</sub>-C<sub>6</sub>)-straight or branched alkyl, (C<sub>2</sub>-C<sub>6</sub>)-straight or branched alkenyl, O-[(C<sub>1</sub>-C<sub>6</sub>)-straight or branched alkyl], O-[(C<sub>3</sub>-C<sub>6</sub>)-straight or branched alkenyl], (CH<sub>2</sub>)<sub>n</sub>-N(R<sup>4</sup>)(R<sup>5</sup>), (CH<sub>2</sub>)<sub>n</sub>-NH(R<sup>4</sup>)-(CH<sub>2</sub>)<sub>n</sub>-Z, (CH<sub>2</sub>)<sub>n</sub>-N(R<sup>4</sup>-(CH<sub>2</sub>)<sub>n</sub>-Z)(R<sup>5</sup>-(CH<sub>2</sub>)<sub>n</sub>-Z), (CH<sub>2</sub>)<sub>n</sub>-Z, O-(CH<sub>2</sub>)<sub>n</sub>-Z,  
15 (CH<sub>2</sub>)<sub>n</sub>-O-Z, S-(CH<sub>2</sub>)<sub>n</sub>-Z, CH=CH-Z, 1,2-methylenedioxy, C(O)OH, C(O)O-[(C<sub>1</sub>-C<sub>6</sub>)-straight or branched alkyl], C(O)O-(CH<sub>2</sub>)<sub>n</sub>-Z or C(O)-N(R<sup>4</sup>)(R<sup>5</sup>);

wherein each of R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, (C<sub>1</sub>-C<sub>6</sub>)-straight or branched alkyl, (C<sub>3</sub>-C<sub>5</sub>)-  
20 straight or branched alkenyl, or wherein R<sup>4</sup> and R<sup>5</sup>, when bound to the same nitrogen atom, are taken together with the nitrogen atom to form a 5 or 6 membered ring, wherein said ring optionally contains 1 to 3 additional heteroatoms independently selected from N, O or S;  
25 wherein said alkyl, alkenyl or alkynyl groups in R<sub>4</sub> and R<sub>5</sub> are optionally substituted with Z.

each n is independently 0 to 4;

each Z is independently selected from a saturated, partially saturated or unsaturated, monocyclic or  
30 bicyclic ring system, wherein each ring comprises 5 to 7 ring atoms independently selected from C, N, O or S; and wherein no more than 4 ring atoms are selected from N, O

or S;

wherein 1 to 4 hydrogen atoms in Z are optionally and independently replaced with halo, hydroxy, nitro, cyano, C(O)OH, (C<sub>1</sub>-C<sub>3</sub>)-straight or branched alkyl, O-(C<sub>1</sub>-C<sub>3</sub>)-straight or branched alkyl, C(O)O-[(C<sub>1</sub>-C<sub>3</sub>)-straight or branched alkyl], amino, NH[(C<sub>1</sub>-C<sub>3</sub>)-straight or branched alkyl], or N-[(C<sub>1</sub>-C<sub>3</sub>)-straight or branched alkyl]<sub>2</sub>.

wherein 1 to 4 hydrogen atoms in the bicyclic ring of formula (I) or formula (II) are optionally and independently replaced with Q;

wherein Q is selected from E, (C<sub>1</sub>-C<sub>6</sub>)-straight or branched alkyl, (C<sub>2</sub>-C<sub>6</sub>)-straight or branched alkenyl or alkynyl, wherein 1 to 2 hydrogen atoms in said alkyl, alkenyl or alkynyl is optionally and independently replaced with E;

wherein Q is optionally substituted with up to 3 substituents selected from halogen, OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(CH<sub>2</sub>)<sub>n</sub>-Z, NO<sub>2</sub>, CO<sub>2</sub>H, C(O)-O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, C(O)NR<sup>4</sup>R<sup>5</sup>, NR<sup>4</sup>R<sup>5</sup> and (CH<sub>2</sub>)<sub>n</sub>-Z; and

wherein the bicyclic rings of formula (I) and formula (II) are optionally be benzo fused.

2. The compound according to claim 1, wherein:

each of A and B is independently selected from -CH<sub>2</sub>-CH<sub>2</sub>-E or -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-E; and

E is a monocyclic or bicyclic aromatic ring system, wherein said ring comprises 5-7 ring atoms independently selected from C, N, O or S, and wherein 1 to 4 ring atoms are independently selected from N, O or S;

wherein 1 to 4 hydrogen atoms in E are optionally and independently replaced with halogen, hydroxyl, hydroxymethyl, nitro, SO<sub>3</sub>H, trifluoromethyl, trifluoromethoxy, (C<sub>1</sub>-C<sub>6</sub>)-straight or branched alkyl,  
5 (C<sub>2</sub>-C<sub>6</sub>)-straight or branched alkenyl, O-[(C<sub>1</sub>-C<sub>6</sub>)-straight or branched alkyl], O-[(C<sub>3</sub>-C<sub>6</sub>)-straight or branched alkenyl], (CH<sub>2</sub>)<sub>n</sub>-N(R<sup>4</sup>)(R<sup>5</sup>), (CH<sub>2</sub>)<sub>n</sub>-NH(R<sup>4</sup>)-(CH<sub>2</sub>)<sub>n</sub>-Z, (CH<sub>2</sub>)<sub>n</sub>-N(R<sup>4</sup>-(CH<sub>2</sub>)<sub>n</sub>-Z)(R<sup>5</sup>-(CH<sub>2</sub>)<sub>n</sub>-Z), (CH<sub>2</sub>)<sub>n</sub>-Z, O-(CH<sub>2</sub>)<sub>n</sub>-Z, (CH<sub>2</sub>)<sub>n</sub>-O-Z, S-(CH<sub>2</sub>)<sub>n</sub>-Z, CH=CH-Z, 1,2-methylenedioxy,  
10 C(O)OH, or C(O)-N(R<sup>4</sup>)(R<sup>5</sup>).

3. The compound according to claim 1 or 2, wherein y is 1.

15 4. The compound according to claim 1 or 2, wherein y is 2.

5. The compound according to claim 2, wherein each of A and B is independently selected from -CH<sub>2</sub>-CH<sub>2</sub>-E or  
20 or -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-E; and  
E is pyridyl.

6. The compound according to claim 1, wherein X is O.

25 7. The compound according to claim 1, wherein X is NR<sup>1</sup>.

8. A composition comprising a compound  
30 according to claim 1 and a carrier.

9. The composition according to claim 8,

further comprising a neurotrophic factor.

10. The composition according to claim 9,  
wherein said neurotrophic factor is selected from nerve  
5 growth factor (NGF), insulin-like growth factor (IGF-1)  
and its active truncated derivatives such as gIGF-1 and  
Des(1-3)IGF-I, acidic and basic fibroblast growth factor  
(aFGF and bFGF, respectively), platelet-derived growth  
factors (PDGF), brain-derived neurotrophic factor (BDNF),  
10 ciliary neurotrophic factors (CNTF), glial cell line-  
derived neurotrophic factor (GDNF), neurotrophin-3 (NT-  
3) and neurotrophin 4/5 (NT-4/5).

11. The composition according to claim 10,  
15 wherein said neurotrophic factor is nerve growth factor  
(NGF).

12. A method for stimulating neuronal  
regeneration in a patient or in an *ex vivo* nerve cell,  
20 comprising the step of administering to said patient or  
said nerve cell a compound according to any one of claims  
1-7.

13. The method according to claim 12, wherein  
25 said compound is administered to a patient and is  
formulated together with a pharmaceutically suitable  
carrier into a pharmaceutically acceptable composition.

14. The method according to claim 13,  
30 comprising the additional step of administering to said  
patient a neurotrophic factor either as part of a

multiple dosage form together with said compound or as a separate dosage form.

15           15. The method according to claim 14, wherein  
5   said neurotrophic factor is selected from nerve growth  
factor (NGF), insulin-like growth factor (IGF-1) and its  
active truncated derivatives such as gIGF-1 and  
Des(1-3)IGF-I, acidic and basic fibroblast growth factor  
(aFGF and bFGF, respectively), platelet-derived growth  
10   factors (PDGF), brain-derived neurotrophic factor (BDNF),  
ciliary neurotrophic factors (CNTF), glial cell line-  
derived neurotrophic factor (GDNF), neurotrophin-3 (NT-  
3) and neurotrophin 4/5 (NT-4/5).

15           16. The method according to claim 15, wherein  
said neurotrophic factor is nerve growth factor (NGF).

            17. The method according to claim 15, wherein  
said method is used to treat a patient suffering from a  
20   disease selected from trigeminal neuralgia,  
glossopharyngeal neuralgia, Bell's Palsy, myasthenia  
gravis, muscular dystrophy, muscle injury, progressive  
muscular atrophy, progressive bulbar inherited muscular  
atrophy, herniated, ruptured, or prolapsed intervertebrae  
25   disk syndrome's, cervical spondylosis, plexus disorders,  
thoracic outlet destruction syndromes, peripheral  
neuropathies, such as those caused by lead, dapsone,  
ticks, or porphyria, other peripheral myelin disorders,  
Alzheimer's disease, Gullain-Barre syndrome, Parkinson's  
30   disease and other Parkinsonian disorders, ALS, Tourette's  
syndrome, multiple sclerosis, other central myelin  
disorders, stroke and ischemia associated with stroke,

neural paropathy, other neural degenerative diseases,  
motor neuron diseases, sciatic crush, neuropathy  
associated with diabetes, spinal cord injuries, facial  
nerve crush and other trauma, chemotherapy- and other  
5 medication-induced neuropathies, and Huntington's  
disease.

18. The method according to claim 17,  
wherein said method is used to stimulate neuronal  
10 regeneration in an ex vivo nerve cell.

19. The method according to claim 18,  
comprising the additional step of contacting said ex vivo  
nerve cell with a neurotrophic factor.

15

20. The method according to claim 19, wherein  
said neurotrophic factor is selected from nerve growth  
factor (NGF), insulin-like growth factor (IGF-1) and its  
active truncated derivatives such as gIGF-1 and  
20 Des(1-3)IGF-I, acidic and basic fibroblast growth factor  
(aFGF and bFGF, respectively), platelet-derived growth  
factors (PDGF), brain-derived neurotrophic factor (BDNF),  
ciliary neurotrophic factors (CNTF), glial cell line-  
derived neurotrophic factor (GDNF), neurotrophin-3 (NT-  
25 3) and neurotrophin 4/5 (NT-4/5).

21. The method according to claim 20, wherein  
said neurotrophic factor is nerve growth factor (NGF).